The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Triggering global regulatory submissions this year for the treatment of obesity
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Subscribe To Our Newsletter & Stay Updated
